Which has higher earnings and valuation, DOCS or GDRX?

Doximity has higher earnings, but lower revenue than GoodRx. Doximity is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Doximity $644.86M 7.09 $196.05M $0.85 30.19 GoodRx $796.85M 1.46 $30.44M $0.04 84.75

Is DOCS or GDRX more profitable?

Doximity has a net margin of 25.48% compared to GoodRx's net margin of 2.07%. Doximity's return on equity of 18.06% beat GoodRx's return on equity. Company Net Margins Return on Equity Return on Assets Doximity 25.48% 18.06% 15.40% GoodRx 2.07% 7.22% 2.53%

Does the media favor DOCS or GDRX?

In the previous week, Doximity had 7 more articles in the media than GoodRx. MarketBeat recorded 10 mentions for Doximity and 3 mentions for GoodRx. GoodRx's average media sentiment score of 1.08 beat Doximity's score of 0.93 indicating that GoodRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Doximity 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, HTFL or GDRX?

GoodRx has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heartflow $176.03M 24.64 -$116.79M -$1.83 N/A GoodRx $796.85M 1.46 $30.44M $0.04 84.75

Is HTFL or GDRX more profitable?

GoodRx has a net margin of 2.07% compared to Heartflow's net margin of -55.82%. GoodRx's return on equity of 7.22% beat Heartflow's return on equity. Company Net Margins Return on Equity Return on Assets Heartflow -55.82% -23.52% -18.66% GoodRx 2.07% 7.22% 2.53%

Does the media prefer HTFL or GDRX?

In the previous week, Heartflow had 11 more articles in the media than GoodRx. MarketBeat recorded 14 mentions for Heartflow and 3 mentions for GoodRx. GoodRx's average media sentiment score of 1.08 beat Heartflow's score of 0.69 indicating that GoodRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heartflow 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SDGR or GDRX?

GoodRx has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Schrodinger $255.87M 5.49 -$103.26M -$0.74 N/A GoodRx $796.85M 1.46 $30.44M $0.04 84.75

Is SDGR or GDRX more profitable?

GoodRx has a net margin of 2.07% compared to Schrodinger's net margin of -20.98%. GoodRx's return on equity of 7.22% beat Schrodinger's return on equity. Company Net Margins Return on Equity Return on Assets Schrodinger -20.98% -16.37% -8.19% GoodRx 2.07% 7.22% 2.53%

Does the media favor SDGR or GDRX?

In the previous week, Schrodinger had 2 more articles in the media than GoodRx. MarketBeat recorded 5 mentions for Schrodinger and 3 mentions for GoodRx. Schrodinger's average media sentiment score of 1.08 beat GoodRx's score of 1.08 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GDRX or CERT?

GoodRx has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GoodRx $796.85M 1.46 $30.44M $0.04 84.75 Certara $418.84M 2.75 -$1.60M -$0.45 N/A

Is GDRX or CERT more profitable?

GoodRx has a net margin of 2.07% compared to Certara's net margin of -16.75%. GoodRx's return on equity of 7.22% beat Certara's return on equity. Company Net Margins Return on Equity Return on Assets GoodRx 2.07% 7.22% 2.53% Certara -16.75% 3.86% 2.65%

Which has better earnings & valuation, TDOC or GDRX?

GoodRx has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teladoc Health $2.53B 0.44 -$200.32M -$0.99 N/A GoodRx $796.85M 1.46 $30.44M $0.04 84.75

Is TDOC or GDRX more profitable?

GoodRx has a net margin of 2.07% compared to Teladoc Health's net margin of -7.13%. GoodRx's return on equity of 7.22% beat Teladoc Health's return on equity. Company Net Margins Return on Equity Return on Assets Teladoc Health -7.13% -12.15% -5.83% GoodRx 2.07% 7.22% 2.53%

Does the media prefer TDOC or GDRX?

In the previous week, Teladoc Health had 3 more articles in the media than GoodRx. MarketBeat recorded 6 mentions for Teladoc Health and 3 mentions for GoodRx. Teladoc Health's average media sentiment score of 1.38 beat GoodRx's score of 1.08 indicating that Teladoc Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teladoc Health 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GoodRx (GDRX) Competitors

$3.39 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.01 (+0.29%)

As of 08:28 AM Eastern

Compare

GDRX vs. DOCS, HTFL, SDGR, CERT, and TDOC

Should you buy GoodRx stock or one of its competitors? GoodRx's main competitors and comparable companies include Doximity (DOCS), Heartflow (HTFL), Schrodinger (SDGR), Certara (CERT), and Teladoc Health (TDOC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does GoodRx compare to Doximity?

Doximity (NYSE:DOCS) and GoodRx (NASDAQ:GDRX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

87.2% of Doximity shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 31.8% of Doximity shares are owned by company insiders. Comparatively, 5.9% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Doximity has higher earnings, but lower revenue than GoodRx. Doximity is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Doximity	$644.86M	7.09	$196.05M	$0.85	30.19
GoodRx	$796.85M	1.46	$30.44M	$0.04	84.75

Doximity has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Doximity has a net margin of 25.48% compared to GoodRx's net margin of 2.07%. Doximity's return on equity of 18.06% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Doximity	25.48%	18.06%	15.40%
GoodRx	2.07%	7.22%	2.53%

Doximity presently has a consensus target price of $32.18, indicating a potential upside of 25.41%. GoodRx has a consensus target price of $4.23, indicating a potential upside of 24.70%. Given Doximity's stronger consensus rating and higher probable upside, analysts plainly believe Doximity is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Doximity	4 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.27
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Doximity had 7 more articles in the media than GoodRx. MarketBeat recorded 10 mentions for Doximity and 3 mentions for GoodRx. GoodRx's average media sentiment score of 1.08 beat Doximity's score of 0.93 indicating that GoodRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Doximity	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Doximity beats GoodRx on 13 of the 17 factors compared between the two stocks.

How does GoodRx compare to Heartflow?

Heartflow (NASDAQ:HTFL) and GoodRx (NASDAQ:GDRX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Heartflow currently has a consensus price target of $44.88, suggesting a potential downside of 10.03%. GoodRx has a consensus price target of $4.23, suggesting a potential upside of 24.70%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heartflow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

GoodRx has a net margin of 2.07% compared to Heartflow's net margin of -55.82%. GoodRx's return on equity of 7.22% beat Heartflow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heartflow	-55.82%	-23.52%	-18.66%
GoodRx	2.07%	7.22%	2.53%

In the previous week, Heartflow had 11 more articles in the media than GoodRx. MarketBeat recorded 14 mentions for Heartflow and 3 mentions for GoodRx. GoodRx's average media sentiment score of 1.08 beat Heartflow's score of 0.69 indicating that GoodRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heartflow	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.8% of GoodRx shares are held by institutional investors. 7.7% of Heartflow shares are held by company insiders. Comparatively, 5.9% of GoodRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GoodRx has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heartflow	$176.03M	24.64	-$116.79M	-$1.83	N/A
GoodRx	$796.85M	1.46	$30.44M	$0.04	84.75

Summary

GoodRx beats Heartflow on 10 of the 16 factors compared between the two stocks.

How does GoodRx compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

GoodRx has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	5.49	-$103.26M	-$0.74	N/A
GoodRx	$796.85M	1.46	$30.44M	$0.04	84.75

Schrodinger has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 10.1% of Schrodinger shares are owned by insiders. Comparatively, 5.9% of GoodRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

GoodRx has a net margin of 2.07% compared to Schrodinger's net margin of -20.98%. GoodRx's return on equity of 7.22% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-20.98%	-16.37%	-8.19%
GoodRx	2.07%	7.22%	2.53%

Schrodinger presently has a consensus target price of $20.50, indicating a potential upside of 7.78%. GoodRx has a consensus target price of $4.23, indicating a potential upside of 24.70%. Given GoodRx's higher possible upside, analysts clearly believe GoodRx is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, Schrodinger had 2 more articles in the media than GoodRx. MarketBeat recorded 5 mentions for Schrodinger and 3 mentions for GoodRx. Schrodinger's average media sentiment score of 1.08 beat GoodRx's score of 1.08 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

GoodRx beats Schrodinger on 9 of the 16 factors compared between the two stocks.

How does GoodRx compare to Certara?

GoodRx (NASDAQ:GDRX) and Certara (NASDAQ:CERT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

63.8% of GoodRx shares are owned by institutional investors. Comparatively, 74.0% of Certara shares are owned by institutional investors. 5.9% of GoodRx shares are owned by company insiders. Comparatively, 1.1% of Certara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

GoodRx presently has a consensus target price of $4.23, suggesting a potential upside of 24.70%. Certara has a consensus target price of $8.28, suggesting a potential upside of 9.64%. Given GoodRx's higher possible upside, research analysts clearly believe GoodRx is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08
Certara	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45

GoodRx has a net margin of 2.07% compared to Certara's net margin of -16.75%. GoodRx's return on equity of 7.22% beat Certara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	2.07%	7.22%	2.53%
Certara	-16.75%	3.86%	2.65%

GoodRx has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Certara has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

In the previous week, GoodRx had 2 more articles in the media than Certara. MarketBeat recorded 3 mentions for GoodRx and 1 mentions for Certara. Certara's average media sentiment score of 1.85 beat GoodRx's score of 1.08 indicating that Certara is being referred to more favorably in the news media.

Company	Overall Sentiment
GoodRx	Positive
Certara	Very Positive

GoodRx has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$796.85M	1.46	$30.44M	$0.04	84.75
Certara	$418.84M	2.75	-$1.60M	-$0.45	N/A

Summary

GoodRx beats Certara on 10 of the 16 factors compared between the two stocks.

How does GoodRx compare to Teladoc Health?

Teladoc Health (NYSE:TDOC) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

Teladoc Health has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

GoodRx has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.53B	0.44	-$200.32M	-$0.99	N/A
GoodRx	$796.85M	1.46	$30.44M	$0.04	84.75

76.8% of Teladoc Health shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 0.7% of Teladoc Health shares are held by insiders. Comparatively, 5.9% of GoodRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

GoodRx has a net margin of 2.07% compared to Teladoc Health's net margin of -7.13%. GoodRx's return on equity of 7.22% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-7.13%	-12.15%	-5.83%
GoodRx	2.07%	7.22%	2.53%

In the previous week, Teladoc Health had 3 more articles in the media than GoodRx. MarketBeat recorded 6 mentions for Teladoc Health and 3 mentions for GoodRx. Teladoc Health's average media sentiment score of 1.38 beat GoodRx's score of 1.08 indicating that Teladoc Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teladoc Health	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teladoc Health presently has a consensus price target of $7.54, suggesting a potential upside of 22.37%. GoodRx has a consensus price target of $4.23, suggesting a potential upside of 24.70%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than Teladoc Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

Summary

GoodRx beats Teladoc Health on 9 of the 16 factors compared between the two stocks.

Get GoodRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GDRX vs. The Competition

Export

Metric	GoodRx	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.16B	$1.70B	$7.15B	$12.84B
Dividend Yield	N/A	4.70%	2.57%	11.71%
P/E Ratio	84.77	20.42	275.28	25.35
Price / Sales	1.46	88.98	646.14	90.72
Price / Cash	8.47	31.57	28.42	34.96
Price / Book	1.87	5.97	10.37	6.21
Net Income	$30.44M	-$18.66M	$3.50B	$358.54M
7 Day Performance	-2.59%	-1.29%	-3.30%	-2.39%
1 Month Performance	-9.12%	1.30%	-0.86%	-3.39%
1 Year Performance	-19.09%	-14.56%	23.53%	8.81%

GoodRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GDRX GoodRx	4.62 of 5 stars	$3.39 flat	$4.23 +24.7%	-19.1%	$1.16B	$796.85M	84.77	697	Positive News
DOCS Doximity	4.6233 of 5 stars	$26.33 -0.1%	$32.43 +23.2%	N/A	$4.70B	$644.86M	30.98	890	Gap Down
HTFL Heartflow	2.046 of 5 stars	$48.91 flat	$43.43 -11.2%	+49.4%	$4.25B	$176.03M	N/A	699	Gap Down
SDGR Schrodinger	1.4561 of 5 stars	$20.09 flat	$20.50 +2.0%	+2.4%	$1.48B	$255.87M	N/A	790	Positive News Gap Down
CERT Certara	1.8019 of 5 stars	$7.94 flat	$8.28 +4.3%	-33.1%	$1.21B	$418.84M	N/A	1,576	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GDRX) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GoodRx (GDRX) Competitors